Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Fortrea Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 was 23.65%.
The industry rank for Fortrea Holdings's 3-Year RORE % or its related term are showing as below:
FTRE's 3-Year RORE % is ranked better than 82.16% of 1289
companies
in the Biotechnology industry
Industry Median: -11.53
vs FTRE: 23.65
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Fortrea Holdings 3-Year RORE % Related Terms
Fortrea Holdings 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Fortrea Holdings's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FTRE vs SEPN, MLTX, URGN: 3-Year RORE % Comparison
For the Biotechnology subindustry, Fortrea Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Fortrea Holdings (FTRE) has a 3-Year RORE % of 23.65 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Fortrea Holdings and its competitors. According to the industry distribution chart, Fortrea Holdings ranks #230 out of 1289 companies in the Biotechnology industry, placing it in the top 17.8%.
Is Fortrea Holdings' 3-Year RORE % too high?
Fortrea Holdings' current 3-Year RORE % is 23.65. Based on the distribution chart, Fortrea Holdings ranks #230 out of 1289 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fortrea Holdings has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' 3-Year RORE % compare to SEPN and MLTX?
According to the Biotechnology industry distribution chart, Fortrea Holdings ranks #230 out of 1289 companies for 3-Year RORE %. This places Fortrea Holdings in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Fortrea Holdings and its competitors. Fortrea Holdings's current 3-Year RORE % is 23.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Based on GuruFocus' analysis, Fortrea Holdings (FTRE) is currently considered Fairly Valued. The stock's GF Value™ is $18.23, compared to a current price of $17.85 — trading 2.1% below its estimated fair value. The current 3-Year RORE % is 23.65. Fortrea Holdings' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Fortrea Holdings (FTRE), the current 3-Year RORE % is 23.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortrea Holdings (FTRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued.
The current stock price of $17.85 is trading 2.1% below its estimated GF Value™ of $18.23.
GuruFocus considers Fortrea Holdings to be Fairly Valued.
Key valuation signals for FTRE:
3-Year RORE %: 23.65
GF Value™: $18.23 vs. price of $17.85 (2.1% below fair value)
No single metric tells the full story. See the FTRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
66GF Score
Get the complete analysis for FTRE
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FTRE has been successfully added to your 
